Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon

Walter H. Ettinger, Robert A Wise, Deborah Schaffhauser, Fredrick Wigley

Research output: Contribution to journalArticle

Abstract

The prostaglandin thromboxane A2 causes platelet aggregation and vasoconstriction and may be important in the pathogenesis of Raynaud's phenomenon. Therefore, a randomized, double-blind, placebo-controlled trial was conducted to assess the effectiveness of dazoxiben, a selective thromboxane synthetase inhibitor, in the treatment of Raynaud's phenomenon and to compare it with nifedipine, a calcium channel blocker. Twenty-two subjects who had at least one episode of Raynaud's phenomenon per day entered the study. Three patients withdrew from the study because of side effects while taking nifedipine. There was no difference among the subjects' subjective evaluation of the three treatments. Seven of 19 (44 percent) reported a moderate to marked improvement while taking placebo compared with 12 of 19 (63 percent) taking nifedipine and five of 19 (26 percent) taking dazoxiben (p = NS). Similarly, there was no difference in the mean two-week episode rate among the three treatments: placebo 30.4 ± 4.5, nifedipine 24.7 ± 5.6, dazoxiben 32.0 ± 4.9 (p = NS). Twelve of 22 subjects experienced side effects while taking nifedipine as compared with two of 21 taking placebo and eight of 21 taking dazoxiben (p

Original languageEnglish (US)
Pages (from-to)451-456
Number of pages6
JournalAmerican Journal of Medicine
Volume77
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Raynaud Disease
Nifedipine
Placebos
Thromboxane-A Synthase
Therapeutics
Thromboxane A2
Calcium Channel Blockers
Vasoconstriction
Platelet Aggregation
dazoxiben

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. / Ettinger, Walter H.; Wise, Robert A; Schaffhauser, Deborah; Wigley, Fredrick.

In: American Journal of Medicine, Vol. 77, No. 3, 1984, p. 451-456.

Research output: Contribution to journalArticle

@article{c2c1b93e912845759300ccca8da1b78f,
title = "Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon",
abstract = "The prostaglandin thromboxane A2 causes platelet aggregation and vasoconstriction and may be important in the pathogenesis of Raynaud's phenomenon. Therefore, a randomized, double-blind, placebo-controlled trial was conducted to assess the effectiveness of dazoxiben, a selective thromboxane synthetase inhibitor, in the treatment of Raynaud's phenomenon and to compare it with nifedipine, a calcium channel blocker. Twenty-two subjects who had at least one episode of Raynaud's phenomenon per day entered the study. Three patients withdrew from the study because of side effects while taking nifedipine. There was no difference among the subjects' subjective evaluation of the three treatments. Seven of 19 (44 percent) reported a moderate to marked improvement while taking placebo compared with 12 of 19 (63 percent) taking nifedipine and five of 19 (26 percent) taking dazoxiben (p = NS). Similarly, there was no difference in the mean two-week episode rate among the three treatments: placebo 30.4 ± 4.5, nifedipine 24.7 ± 5.6, dazoxiben 32.0 ± 4.9 (p = NS). Twelve of 22 subjects experienced side effects while taking nifedipine as compared with two of 21 taking placebo and eight of 21 taking dazoxiben (p",
author = "Ettinger, {Walter H.} and Wise, {Robert A} and Deborah Schaffhauser and Fredrick Wigley",
year = "1984",
doi = "10.1016/0002-9343(84)90101-3",
language = "English (US)",
volume = "77",
pages = "451--456",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon

AU - Ettinger, Walter H.

AU - Wise, Robert A

AU - Schaffhauser, Deborah

AU - Wigley, Fredrick

PY - 1984

Y1 - 1984

N2 - The prostaglandin thromboxane A2 causes platelet aggregation and vasoconstriction and may be important in the pathogenesis of Raynaud's phenomenon. Therefore, a randomized, double-blind, placebo-controlled trial was conducted to assess the effectiveness of dazoxiben, a selective thromboxane synthetase inhibitor, in the treatment of Raynaud's phenomenon and to compare it with nifedipine, a calcium channel blocker. Twenty-two subjects who had at least one episode of Raynaud's phenomenon per day entered the study. Three patients withdrew from the study because of side effects while taking nifedipine. There was no difference among the subjects' subjective evaluation of the three treatments. Seven of 19 (44 percent) reported a moderate to marked improvement while taking placebo compared with 12 of 19 (63 percent) taking nifedipine and five of 19 (26 percent) taking dazoxiben (p = NS). Similarly, there was no difference in the mean two-week episode rate among the three treatments: placebo 30.4 ± 4.5, nifedipine 24.7 ± 5.6, dazoxiben 32.0 ± 4.9 (p = NS). Twelve of 22 subjects experienced side effects while taking nifedipine as compared with two of 21 taking placebo and eight of 21 taking dazoxiben (p

AB - The prostaglandin thromboxane A2 causes platelet aggregation and vasoconstriction and may be important in the pathogenesis of Raynaud's phenomenon. Therefore, a randomized, double-blind, placebo-controlled trial was conducted to assess the effectiveness of dazoxiben, a selective thromboxane synthetase inhibitor, in the treatment of Raynaud's phenomenon and to compare it with nifedipine, a calcium channel blocker. Twenty-two subjects who had at least one episode of Raynaud's phenomenon per day entered the study. Three patients withdrew from the study because of side effects while taking nifedipine. There was no difference among the subjects' subjective evaluation of the three treatments. Seven of 19 (44 percent) reported a moderate to marked improvement while taking placebo compared with 12 of 19 (63 percent) taking nifedipine and five of 19 (26 percent) taking dazoxiben (p = NS). Similarly, there was no difference in the mean two-week episode rate among the three treatments: placebo 30.4 ± 4.5, nifedipine 24.7 ± 5.6, dazoxiben 32.0 ± 4.9 (p = NS). Twelve of 22 subjects experienced side effects while taking nifedipine as compared with two of 21 taking placebo and eight of 21 taking dazoxiben (p

UR - http://www.scopus.com/inward/record.url?scp=0021237785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021237785&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(84)90101-3

DO - 10.1016/0002-9343(84)90101-3

M3 - Article

C2 - 6540986

AN - SCOPUS:0021237785

VL - 77

SP - 451

EP - 456

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -